The DOI matches its Crossref record; 57 of the 59 references it cites were found in a registry or an index.
Parkinson's Disease α-Synuclein Transgenic Mice Develop Neuronal Mitochondrial Degeneration and Cell Death
Open accessAbstract
α-Synuclein (α-Syn) is enriched in nerve terminals. Two mutations in the α-Syn gene (Ala53→ Thr and Ala30→ Pro) occur in autosomal dominant familial Parkinson's disease. Mice overexpressing the human A53T mutant α-Syn develop a severe movement disorder, paralysis, and synucleinopathy, but the mechanisms are not understood. We examined whether transgenic mice expressing human wild-type or familial Parkinson's disease-linked A53T or A30P mutant α-syn develop neuronal degeneration and cell death. Mutant mice were examined at early- to mid-stage disease and at near end-stage disease. Age-matched nontransgenic littermates were controls. In A53T mice, neurons in brainstem and spinal cord exhibited large axonal swellings, somal chromatolytic changes, and nuclear condensation. Spheroid eosinophilic Lewy body-like inclusions were present in the cytoplasm of cortical neurons and spinal motor neurons. These inclusions contained human α-syn and nitrated synuclein. Motor neurons were depleted (∼75%) in A53T mice but were affected less in A30P mice. Axonal degeneration was present in many regions. Electron microscopy confirmed the cell and axonal degeneration and revealed cytoplasmic inclusions in dendrites and axons. Some inclusions were degenerating mitochondria and were positive for humanα-syn. Mitochondrial complex IV and V proteins were at control levels, but complex IV activity was reduced significantly in spinal cord. Subsets of neurons in neocortex, brainstem, and spinal cord ventral horn were positive for terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling, cleaved caspase-3, and p53. Mitochondria in neurons had terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling-positive matrices and p53 at the outer membrane. Thus, A53T mutant mice develop intraneuronal inclusions, mitochondrial DNA damage and degeneration, and apoptotic-like death of neocortical, brainstem, and motor neurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Mitochondrial degeneration has been implicated in a-synucleinopathy (13,25) and a-syn transgenic flies show abnormal mitochondrial morphology (16).”
From Enhanced mTORC1 signaling and Protein Synthesis in Parkinson’s Disease Pathogenesis Disease Pathogenesis (2022) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“p53 can mediate mitochondrial membrane permeabilization and apoptosis by activating Bax and Bak (Chipuk et al., 2004; Leu et al., 2004).”
BackgroundMasliah, E., Rockenstein, E. M., Veinbergs, I., Mallory, M. E., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,779
p53 Has a Direct Apoptogenic Role at the Mitochondria
Mihara, M., Erster, S. H., Zaika, A. I., Petrenko, O., Chittenden, T. D., Pančoška, P., & Moll, U. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00050-9 · Cited by 1,771
Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal
Maroteaux, L., Campanelli, J., & Scheller, R. (1988) · Journal of Neuroscience · doi:10.1523/jneurosci.08-08-02804.1988 · Cited by 1,646
Giasson, B. I., Duda, J. E., Murray, I. V. J., Chen, Q., Souza, J. M., Hurtig, H. I., Ischiropoulos, H., Trojanowski, J. Q., & Lee, V. M. ‐. (2000) · Science · doi:10.1126/science.290.5493.985 · Cited by 1,567
Alpha-synuclein and neurodegenerative diseases
Goedert, M. (2001) · Nature reviews. Neuroscience · doi:10.1038/35081564 · Cited by 1,428
Flagged first, then by citations
2 of the 59 references couldn’t be matched to a known paper.
Research works printed but not linked: 6
- Chayen J, Bitensky L, Butcher R (1973) Practical histochemistry. New York: Wiley.
- 2001, Int J Mol Med, 7, 455
- 2002, J Neurobiol, 5, 181
- 2002, Neurochem Res, 27, 1089
- 1997, J Comp Neurol, 378, 70
- 2000, J Biol Chem, 265, 18344
Cited by
Sorted by citations
Items 101–200 of 684
The concept of alpha-synuclein as a prion-like protein: ten years after
Steiner, J. A., Quansah, E., & Brundin, P. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2814-1 · Cited by 183
Gan, L., Vargas, M. R., Johnson, D. A., & Johnson, J. A. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.3049-12.2012 · Cited by 189
The role of mitochondria in inherited neurodegenerative diseases
Kwong, J. Q., Beal, M. F., & Manfredi, G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03990.x · Cited by 180
Hung, L. W., Villemagne, V. L., Cheng, L., Sherratt, N. A., Ayton, S., White, A. R., Crouch, P. J., Lim, S., Leong, S. L., Wilkins, S., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112285 · Cited by 177
Alpha-synuclein spreading in Parkinson’s disease
Recasens, A., & Dehay, B. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00159 · Cited by 192
Genetics and genomics of Parkinson’s disease
Lin, M. K., & Farrer, M. J. (2014) · Genome Medicine · doi:10.1186/gm566 · Cited by 183
Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage
Stichel, C. C., Zhu, X., Bader, V., Linnartz‐Gerlach, B., Schmidt, S., & Lübbert, H. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm083 · Cited by 183
Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
Devoto, V. M. P., & Falzone, T. L. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.026294 · Cited by 184
APOE genotype regulates pathology and disease progression in synucleinopathy
Davis, A. A., Inman, C. E., Wargel, Z. M., Dube, U., Freeberg, B. M., Galluppi, A., Haines, J. N., Dhavale, D. D., Miller, R., Choudhury, F. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay3069 · Cited by 177
Su, L. J., Auluck, P. K., Outeiro, T. F., Yeger‐Lotem, E., Kritzer, J. A., Tardiff, D. F., Strathearn, K. E., Liu, F., Cao, S., Hamamichi, S., et al. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.004267 · Cited by 180
Synaptic pathology: A shared mechanism in neurological disease
Henstridge, C. M., Pickett, E. K., & Spires‐Jones, T. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.04.005 · Cited by 176
Alzheimer's and Parkinson's disease therapies in the clinic
Chopade, P., Chopade, N., Zhao, Z., Mitragotri, S., Liao, R., & Suja, V. C. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10367 · Cited by 187
Parkinson’s disease: genetic versus toxin‐induced rodent models
Terzioglu, M., & Galter, D. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06302.x · Cited by 173
Béraud, D., Hathaway, H. A., Trecki, J., Chasovskikh, S., Johnson, D. A., Johnson, J. A., Federoff, H. J., Shimoji, M., Mhyre, T. R., & Maguire‐Zeiss, K. A. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9401-0 · Cited by 179
Yang, L., Calingasan, N. Y., Thomas, B., Chaturvedi, R. K., Kiaei, M., Wille, E. J., Liby, K. T., Williams, C. R., Royce, D. B., Risingsong, R., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005757 · Cited by 173
Perfeito, R., Cunha‐Oliveira, T., & Rego, A. C. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.042 · Cited by 169
Biology of Mitochondria in Neurodegenerative Diseases
Martin, L. J. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00005-9 · Cited by 164
Self-citationMitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols
Camilleri, A., Zarb, C., Caruana, M., Ostermeier, U., Ghio, S., Högen, T., Schmidt, F., Giese, A., & Vassallo, N. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.026 · Cited by 166
Circadian disruption and human health: A bidirectional relationship
Abbott, S. M., Malkani, R. G., & Zee, P. C. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14298 · Cited by 161
Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells
Shaik, S., Brown‐Borg, H. M., Ebadi, M., & Porter, J. E. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.05.005 · Cited by 164
Mitochondria and Programmed Cell Death in Parkinson's Disease: Apoptosis and Beyond
Perier, C., Bové, J., & Vila, M. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4074 · Cited by 164
Increased Oxidative Stress Exacerbates α-Synuclein Aggregation In Vivo
Scudamore, O., & Ciossek, T. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly024 · Cited by 163
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
Cole, T. A., Zhao, H. T., Collier, T. J., Sandoval, I. M., Sortwell, C. E., Steece‐Collier, K., Daley, B. F., Booms, A., Lipton, J. W., Welch, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.135633 · Cited by 171
Zhang, Q.-S., Heng, Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2016.11.002 · Cited by 156
Marongiu, R., Spencer, B. J., Crews, L. A., Adame, A., Patrick, C., Trejo, M., Dallapiccola, B., Valente, E. M., & Masliah, E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05932.x · Cited by 157
Redox Control of the Survival of Healthy and Diseased Cells
Zhang, Y., Du, Y., Le, W., Wang, K., Kieffer, N., & Zhang, J. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3685 · Cited by 161
Mitochondrial dysfunction within the synapses of substantia nigra neurons in Parkinson’s disease
Reeve, A. K., Grady, J. P., Cosgrave, E., Bennison, E., Chen, C., Hepplewhite, P. D., & Morris, C. M. (2018) · npj Parkinson s Disease · doi:10.1038/s41531-018-0044-6 · Cited by 157
Mazzulli, J. R., Mishizen-Eberz, A. J., Giasson, B. I., Lynch, D. R., THOMAS, S. A., Nakashima, A., Nagatsu, T., Ota, A., & Ischiropoulos, H. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0896-06.2006 · Cited by 152
Xie, W., & Chung, K. K. K. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07769.x · Cited by 151
TOM40 Mediates Mitochondrial Dysfunction Induced by α-Synuclein Accumulation in Parkinson’s Disease
Bender, A., Desplats, P., Spencer, B. J., Rockenstein, E. M., Adame, A., Elstner, M., Laub, C., Mueller, S. K., Koob, A. O., Mante, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062277 · Cited by 151
RetractedDevi, L., & Anandatheerthavarada, H. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.007 · Cited by 149
Wong, A. S. L., Lee, R. H. K., Cheung, A. Y., Yeung, P. K. K., Chung, S. K., Cheung, Z. H., & Ip, N. Y. (2011) · Nature Cell Biology · doi:10.1038/ncb2217 · Cited by 155
Neuronal death: where does the end begin?
Conforti, L., Adalbert, R., & Coleman, M. P. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.02.004 · Cited by 152
Dysfunction of Cellular Proteostasis in Parkinson’s Disease
Lehtonen, Š., Sonninen, T.-M., Wojciechowski, S., Goldsteins, G., & Koıstınaho, J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00457 · Cited by 152
α-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease
Mullin, S., & Schapira, A. H. V. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8394-x · Cited by 158
Mitochondrial Contribution to Parkinson's Disease Pathogenesis
Schapira, A. H. V., & Gegg, M. E. (2011) · Parkinson s Disease · doi:10.4061/2011/159160 · Cited by 155
Parkinson’s disease and enhanced inflammatory response
Stojkovska, I., Wagner, B. M., & Morrison, B. E. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215576313 · Cited by 149
Role of p53 in Neurodegenerative Diseases
Chang, J. R., Ghafouri, M., Mukerjee, R., Bagashev, A., Chabrashvili, T., & Sawaya, B. E. (2011) · Neurodegenerative Diseases · doi:10.1159/000329999 · Cited by 149
Martinez, B., Petersen, D., Gaeta, A. L., Stanley, S. P., Caldwell, G. A., & Caldwell, K. A. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1294-17.2017 · Cited by 144
A Mitocentric View of Parkinson's Disease
Haelterman, N. A. T., Yoon, W. H., Sandoval, H., Jaiswal, M., Shulman, J. M., & Bellen, H. J. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071013-014317 · Cited by 141
Muntané, G., Dalfó, E., Martı́nez, A., & Ferrer, I. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.01.030 · Cited by 143
The Mitochondrial Chaperone Protein TRAP1 Mitigates α-Synuclein Toxicity
Butler, E. K., Voigt, A., Lutz, A. K., Toegel, J. P., Gerhardt, E., Karsten, P., Falkenburger, B. H., Reinartz, A., Winklhofer, K. F., & Schulz, J. B. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002488 · Cited by 144
Malkus, K. A., Tsika, E., & Ischiropoulos, H. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-24 · Cited by 144
The role of mitochondria in neurodegenerative diseases
Filosto, M., Scarpelli, M., Cotelli, M. S., Vielmi, V., Todeschini, A., Gregorelli, V., Tonin, P., Tomelleri, G., & Padovani, A. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6104-z · Cited by 142
Mitochondrial Dysfunction and Parkinson’s Disease: Pathogenesis and Therapeutic Strategies
Vastegani, S. M., Nasrolahi, A., Ghaderi, S., Belali, R., Rashno, M., Farzaneh, M., & Khoshnam, S. E. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03904-0 · Cited by 149
Genetic mouse models of Parkinson’s disease
Magen, I., & Chesselet, M. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84004-x · Cited by 140
Unique copper‐induced oligomers mediate alpha‐synuclein toxicity
Wright, J. A., Wang, X., & Brown, D. R. (2009) · The FASEB Journal · doi:10.1096/fj.09-130039 · Cited by 140
Jin, M., Li, N., Sheng, W., Ji, X., Liang, X. H., Kong, B., Yin, P., Li, Y., Zhang, X., & Liu, K. (2020) · Environment International · doi:10.1016/j.envint.2020.106179 · Cited by 141
Schiesling, C., Kieper, N., Seidel, K., & Krüger, R. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00952.x · Cited by 143
M itochondrial DNA and primary mitochondrial dysfunction in P arkinson's disease
Giannoccaro, M. P., Morgia, C. L., Rizzo, G., & Carelli, V. (2017) · Movement Disorders · doi:10.1002/mds.26966 · Cited by 137
Liu, W., Vives-Bauzá, C., Acín‐Pérez, R., Yamamoto, A., Tan, Y.-C., Li, Y., Magrané, J., Stavarache, M. A., Shaffer, S., Chang, S. H., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004597 · Cited by 139
Models of α-synuclein aggregation in Parkinson’s disease
Giráldez‐Pérez, R. M., Antolín‐Vallespín, M., Muñoz, M.-D., & Sánchez‐Capelo, A. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0176-9 · Cited by 140
Mitochondrial alterations in Parkinson’s disease: new clues
Vila, M., Ramonet, D., & Perier, C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05604.x · Cited by 131
Laar, V. S. V., & Berman, S. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.015 · Cited by 137
Briston, T., & Hicks, A. R. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180025 · Cited by 131
Animal Models of Parkinson's Disease: Vertebrate GeneticsPreprint
Lee, Y., Dawson, V. L., & Dawson, T. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009324 · Cited by 134
Zhang, L., Zhang, C., Zhu, Y., Cai, Q., Chan, P., Uéda, K., Yu, S., & Yang, H. (2008) · Brain Research · doi:10.1016/j.brainres.2008.08.067 · Cited by 130
α-Synuclein and Neuronal Cell Death
Yasuda, T., Nakata, Y., & Mochizuki, H. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8327-0 · Cited by 131
Structural correlates of facial emotion recognition deficits in Parkinson's disease patients
Baggio, H. C., Segura, B., Ibarretxe-Bilbao, N., Valldeoriola, F., Marti, M. J., Compta, Y., Tolosa, E., & Junqué, C. (2012) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2012.05.020 · Cited by 128
Targeting mitophagy in Parkinson's disease
Clark, E. H., de la Torre, A. V., Hoshikawa, T., & Briston, T. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.014294 · Cited by 132
Han, R., Liang, J., & Zhou, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115887 · Cited by 125
Ciron, C., Lengacher, S., Dusonchet, J., Aebischer, P., & Schneider, B. L. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr618 · Cited by 128
Tapias, V., Hu, X., Luk, K. C., Sanders, L. H., Lee, V. M., & Greenamyre, J. T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2541-x · Cited by 126
α-Synucleinopathy models and human neuropathology: similarities and differences
Kahle, P. J. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0302-x · Cited by 132
α-Synuclein and Mitochondria: Partners in Crime?
Nakamura, K. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0182-9 · Cited by 129
Martin, L. J., Semenkow, S., Hanaford, A. R., & Wong, M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.008 · Cited by 126
Self-citationRole of Matrix Metalloproteinase 3-mediated α-Synuclein Cleavage in Dopaminergic Cell Death
Choi, D.-H., Kim, Y.-J., Kim, Y.-G., Joh, T. H., Beal, M. F., & Kim, Y.-S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.222430 · Cited by 123
Nagatsu, T., & Sawada, M. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9061-9 · Cited by 122
Chapter 6 Molecular and Cellular Biology of Synucleins
Surguchov, A. P. (2008) · International review of cytology · doi:10.1016/s1937-6448(08)01406-8 · Cited by 123
Age-Dependent Effects of A53T Alpha-Synuclein on Behavior and Dopaminergic Function
Oaks, A. W., Frankfurt, M., Finkelstein, D. I., & Sidhu, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060378 · Cited by 117
Dynamics of Human Mitochondrial Complex I Assembly: Implications for Neurodegenerative Diseases
Giachin, G., Bouverot, R., Acajjaoui, S., Pantalone, S., & Soler‐López, M. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2016.00043 · Cited by 118
Loeb, V., Yakunin, E., Saada, A., & Sharon, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.061051 · Cited by 124
Oxidative Stress, Mitochondrial Dysfunction and the Mitochondria Theory of Aging
Kong, Y., Trabucco, S. E., & Zhang, H. (2014) · Interdisciplinary topics in gerontology and geriatrics · doi:10.1159/000358901 · Cited by 117
Mitochondria: A Therapeutic Target for Parkinson’s Disease?
Luo, Y., Hoffer, A., Hoffer, B. J., & Qi, X. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920704 · Cited by 108
Cellular and molecular pathophysiology in the progression of Parkinson’s disease
Zaman, V., Shields, D. C., Shams, R., Drasites, K. P., Matzelle, D. D., Haque, A., & Banik, N. L. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00689-5 · Cited by 119
Cardiolipin Promotes Pore-Forming Activity of Alpha-Synuclein Oligomers in Mitochondrial Membranes
Ghio, S., Camilleri, A., Caruana, M., Ruf, V., Schmidt, F., Leonov, A., Ryazanov, S., Griesinger, C., Cauchi, R. J., Kamp, F., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00320 · Cited by 108
Parkinsonism genes: culprits and clues
Abeliovich, A., & Beal, M. F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04102.x · Cited by 110
Perfeito, R., Cunha‐Oliveira, T., & Rego, A. C. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.08.569 · Cited by 109
Carlo, M. D., Giacomazza, D., Picone, P., Nuzzo, D., & Biagio, P. L. S. (2012) · Free Radical Research · doi:10.3109/10715762.2012.714466 · Cited by 106
The Centrality of Mitochondria in the Pathogenesis and Treatment of Parkinson's Disease
Camilleri, A., & Vassallo, N. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12264 · Cited by 106
Ferrer, I. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.02.004 · Cited by 108
Interaction of misfolded proteins and mitochondria in neurodegenerative disorders
Abramov, A. Y., Berezhnov, A. V., Fedotova, E. I., Зинченко, В. П., & Долгачева, Л. П. (2017) · Biochemical Society Transactions · doi:10.1042/bst20170024 · Cited by 109
Synucleinopathies: Where we are and where we need to go
Brás, I. C., Dominguez‐Meijide, A., Gerhardt, E., Koss, D. J., Lázaro, D. F., Santos, P. I., Vasili, E., Xylaki, M., & Outeiro, T. F. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14965 · Cited by 106
Unravelling mitochondrial pathways to P arkinson's disease
Celardo, I., Martins, L. M., & Gandhi, S. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12433 · Cited by 105
Finkelstein, D. I., Billings, J. L., Adlard, P. A., Ayton, S., Sedjahtera, A., Masters, C. L., Wilkins, S., Shackleford, D. M., Charman, S. A., Bal, W., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0456-2 · Cited by 104
The usual suspects, dopamine and alpha‐synuclein, conspire to cause neurodegeneration
Mor, D. E., Daniels, M. J., & Ischiropoulos, H. (2019) · Movement Disorders · doi:10.1002/mds.27607 · Cited by 107
Kim, B., Jeong, Y. E., Wong, M., & Martin, L. J. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0874-4 · Cited by 109
Self-citationMitochondrial DNA, base excision repair and neurodegeneration
de Souza-Pinto, N. C., Wilson, D. M., Stevnsner, T., & Bohr, V. A. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.03.011 · Cited by 102
α-Synuclein: A Multifunctional Player in Exocytosis, Endocytosis, and Vesicle Recycling
Huang, M., Wang, B., Li, X., Fu, C., Wang, C., & Kang, X. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00028 · Cited by 106
Vekrellis, K., Xilouri, M., Emmanouilidou, E., & Stefanis, L. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06054.x · Cited by 101
Daher, J. P. L., Ying, M., Banerjee, R., McDonald, R. S., Hahn, M. D., Yang, L., Beal, M. F., Thomas, B., Dawson, V. L., Dawson, T. M., et al. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-34 · Cited by 95
p53 in neurodegenerative diseases and brain cancers
Checler, F., & da Costa, C. A. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.009 · Cited by 99
Devoto, V. M. P., Dimopoulos, N. A., Alloatti, M., Pardi, M. B., Saez, T. M. M., Otero, M. G., Cromberg, L. E., Marín‐Burgin, A., Scassa, M. É., Stokin, G. B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05334-9 · Cited by 98
Nair, V. D., McNaught, K. S. P., González‐Maeso, J., Sealfon, S. C., & Olanow, C. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603950200 · Cited by 101
Hu, D., Sun, X., Liao, X., Zhang, X., Zarabi, S. F., Schimmer, A. D., Hong, Y., Ford, C., Luo, Y., & Qi, X. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01993-2 · Cited by 96
Functional and Pathological Effects of α-Synuclein on Synaptic SNARE Complexes
Gao, V., Briano, J. A., Komer, L. E., & Burré, J. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167714 · Cited by 104
Neurodegenerative phenotypes in an A53T -synuclein transgenic mouse model are independent of LRRK2
Daher, J. P. L., Pletniková, O., Biskup, S., Musso, A., Gellhaar, S., Galter, D., Troncoso, J. C., Lee, M. K., Dawson, T. M., Dawson, V. L., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds057 · Cited by 92
Self-citationPGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein
Ciron, C., Zheng, L., Bobela, W., Knott, G. W., Leone, T. C., Kelly, D. P., & Schneider, B. L. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0200-8 · Cited by 98
Helley, M., Pinnell, J. R., Sportelli, C., & Tieu, K. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00177 · Cited by 98
Neuroprotective Properties of Green Tea (Camellia sinensis) in Parkinson’s Disease: A Review
Malar, D. S., Prasanth, M. I., Brimson, J. M., Sharika, R., Sivamaruthi, B. S., Chaiyasut, C., & Tencomnao, T. (2020) · Molecules · doi:10.3390/molecules25173926 · Cited by 97
Metadata
- Authors
- Martin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L., & Lee, M. K.
- Affiliations
- Johns Hopkins University (US)
- National Institutes of Health (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2006-01-04
- Volume
- 26
- Issue
- 1
- Pages
- 41-50
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6381830
- OpenAlex
- W2084910880
- Cited by
- 684
- References
- 59
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 24 · 2023: 27 · 2022: 37 · 2021: 34 · 2020: 27 · 2019: 34 · 2018: 39 · 2017: 43 · 2016: 34 · 2015: 30 · 2014: 35 · 2013: 41 · 2012: 49
- FWCI
- 26.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (NS38377)
- U.S. Public Health Service
- National Institute on Aging (AG 16282, R01AG016282)
- National Institute of Neurological Disorders and Stroke (NS 38377, R01NS052098, NS34 100, P01NS038065, R56NS038065, P50NS038377, NS 38065, R01NS034100, R01NS038065, NS52098)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- alpha-synuclein, Parkinson's disease, A53T mutation, A30P mutation, transgenic mice, mitochondrial degeneration, neuronal cell death, motor neuron degeneration, axonal degeneration, Lewy bodies, mitochondrial DNA damage, apoptosis, caspase-3, p53, mitochondrial complex IV, synucleinopathies
- MeSH terms
- Alanine, Animals, Brain Stem, DNA Damage, Humans, Mice, Transgenic, Mitochondria, Mutation, Nerve Degeneration, Parkinson Disease, Threonine, Cell Death, Neocortex, Mice, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
